Detalhe da pesquisa
1.
Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Breast Cancer Res Treat
; 168(3): 625-630, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29275435